Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2025
May 07, 2024 at 02:00 am EDT
Share
Kissei Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first half and full year of Fiscal Year Ending March 31, 2025. For the first half, the company expected net sales of JPY 41,000 million, Operating profit of JPY 1,500 million, Profit attributable to owners of parent of JPY 5,200 million and Basic earnings per share of JPY 117.63.
For the Full year, the company expected net sales of JPY 83,000 million, Operating profit of JPY 4,200 million, Profit attributable to owners of parent of JPY 11,300 million and Basic earnings per share of JPY 255.62.
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
KISSEI PHARMACEUTICAL CO., LTD. 
